cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-2-85-88cardiovascular-182Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПАТОГЕНЕТИЧЕСКАЯ ТЕРАПИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: МЕСТО АНТАГОНИСТОВ КАЛЬЦИЯPATHOGENETIC TREATMENT OF ARTERIAL HYPERTENSION: THE PLACE OF CALCIUM ANTAGONISTSТаратухинЕ. О.TaratukhinE. O.

кардиолог, к. м.н., ассистент кафедры госпитальной терапии № 1 лечебного факультета

cardio03@list.ruТепловаН. Н.TeplovaN. N.

нефролог, к. м.н., доцент кафедры

Российский национальный исследовательский медицинский университет им. Н. И. Пирогова, МоскваN. I. Pirogov National Medical Research University2013200420131228588Copyright © Таратухин Е.О., Теплова Н.Н., 20132013Таратухин Е.О., Теплова Н.Н.Taratukhin E.O., Teplova N.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/182

В статье приводятся данные о принципиальных аспектах патогенеза артериальной гипертензии и описываются подходы к терапевтическому воздействию на них. Обсуждается роль повышения периферического сопротивления сосудов и гиперволемии как факторов, на которые можно воздействовать блокаторами кальциевых каналов. Приводятся новые данные об этом классе препаратов, в частности, о третьем их поколении. 

The paper describes the key aspects of arterial hypertension pathogenesis and the relevant therapeutic strategies. The authors discuss the role of increased peripheral vascular resistance and hypervolemia as factors which can be targeted by calcium channel blockers. The new evidence on this medication class, including the third-generation calcium antagonists, is presented. 

вазоспазмгиперволемиягипернатриемиясердечный выбросvasospasmhypervolemiahypernatremiacardiac outputReferencesLibby P, Bonow RO, Mann DL, et al. Braunwald’s Heart Disease (8th ed.). Elsevier, 2008. 2274 p.Libby P, Bonow RO, Mann DL, et al. Braunwald’s Heart Disease (8th ed.). Elsevier, 2008. 2274 p.Franklin SS, Pio JR, Wong ND, et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 2005; 111: 1121–7.Franklin SS, Pio JR, Wong ND, et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 2005; 111: 1121–7.McEniery CM, Yasmin, Wallace S, et al. Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension 2005; 46: 221–6.McEniery CM, Yasmin, Wallace S, et al. Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension 2005; 46: 221–6.Gordeev IG, Shaydyuk OYu, Taratukhin EO. Sleep apnea syndrome and cardiovascular pathology: modern insight. Russian Journal of Cardiology 2012; 6: 5–12. Russian (Гордеев И. Г., Шайдюк О. Ю., Таратухин Е. О. Синдром апноэ во сне и кардиологическая патология: современный взгляд. Российский кардиологический журнал 2012; 6: 5–12).Gordeev IG, Shaydyuk OYu, Taratukhin EO. Sleep apnea syndrome and cardiovascular pathology: modern insight. Russian Journal of Cardiology 2012; 6: 5–12. Russian (Гордеев И. Г., Шайдюк О. Ю., Таратухин Е. О. Синдром апноэ во сне и кардиологическая патология: современный взгляд. Российский кардиологический журнал 2012; 6: 5–12).Feig DI, Kang DH, Nakagawa T, et al. Uric acid and hypertension. Curr Hypertens Rep 2006; 8: 111–6.Feig DI, Kang DH, Nakagawa T, et al. Uric acid and hypertension. Curr Hypertens Rep 2006; 8: 111–6.Duprez DA. Role of renin-angiotensin-aldosterone system in vascular remodelling and inflammation. J Hypertens 2006; 24: 983–92.Duprez DA. Role of renin-angiotensin-aldosterone system in vascular remodelling and inflammation. J Hypertens 2006; 24: 983–92.Lüpker RV, Steffen LM, Jacobs DR Jr, et al. Trends in blood pressure and hypertension detection, treatment and control 1980–2009: the Minnesota Heart Survey. Circulation 2012; 126 (15): 1852–7.Lüpker RV, Steffen LM, Jacobs DR Jr, et al. Trends in blood pressure and hypertension detection, treatment and control 1980–2009: the Minnesota Heart Survey. Circulation 2012; 126 (15): 1852–7.Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combiation in the treatment of patients with essential hypertension. Arzneimittelforschung 2010; 60: 124–30.Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combiation in the treatment of patients with essential hypertension. Arzneimittelforschung 2010; 60: 124–30.Lobanova EG, Chekalina ND. Contemporary aspects for the calcium channel blockers pharmacology. Web-publication. Russian (Лобанова ЕГ, Чекалина НД. Современные аспекты фармакологии блокаторов кальциевых каналов. Электронная публикация URL: www.rlsnet.ru/ articles_435.htm — обр. 20.01.2013).Lobanova EG, Chekalina ND. Contemporary aspects for the calcium channel blockers pharmacology. Web-publication. Russian (Лобанова ЕГ, Чекалина НД. Современные аспекты фармакологии блокаторов кальциевых каналов. Электронная публикация URL: www.rlsnet.ru/ articles_435.htm — обр. 20.01.2013).Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag 2005; 1: 173–82.Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag 2005; 1: 173–82.Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh 2012; 6: 449–55.Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh 2012; 6: 449–55.Minushkina LO, Iosava IK. Lercanidipine in arterial hypertension. Kardiologia 2012; 52: 70–4. Russian (Минушкина ЛО, Иосава ИК. Лерканидипин в лечении артериальной гипертензии. Кардиология 2012; 52: 70–4).Minushkina LO, Iosava IK. Lercanidipine in arterial hypertension. Kardiologia 2012; 52: 70–4. Russian (Минушкина ЛО, Иосава ИК. Лерканидипин в лечении артериальной гипертензии. Кардиология 2012; 52: 70–4).Sansanayudh N, Wongwiwatthananukit S, Veerayuthvilai S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 6: 84–92.Sansanayudh N, Wongwiwatthananukit S, Veerayuthvilai S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 6: 84–92.Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol 2011; 31: 561–7.Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol 2011; 31: 561–7.Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.Shetty PK, Suthar NA, Menon J, et al. Transdermal delivery of lercanidipine hydrochloride. Curr Drug Deliv 2013; Jan 3.Shetty PK, Suthar NA, Menon J, et al. Transdermal delivery of lercanidipine hydrochloride. Curr Drug Deliv 2013; Jan 3.

The authors declare that there are no conflicts of interest present.